Dose Escalation of Octreotide Acetate for Management of Gastro-enteropancreatic Neuroendocrine Tumors

Chadha, Manpreet K.; Chadha, Krishdeep; Lombardo, Jeffrey; Mashtare, Terry; Wilding, Gregory E.; Gibbs, John L.; Kuvshinoff, Boris W.; Litwin, Alan; Raczyk, Cheryl; Javle, Milind; Iyer, Renuka

doi:10.14309/00000434-200910003-00268

Cited by 17 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, dosage escalation did not cause significant changes in adverse events or tolerability while providing beneficial improvement in efficacy. A recent retrospective study by Strosberg et al 6 of more than 230 NET patients treated with above-standard doses of octreotide LAR of 30 mg every 4 weeks resulted in improved symptoms of carcinoid syndrome without adverse events, which was consistent with other studies by Chadha et al 7 and Ferolla et al 8 In patients with uncontrolled symptoms or increasing tumor burden, measurement of plasma or serum octreotide level may help physicians consider increasing the dosage further beyond the recommended dosage. Studies have demonstrated that plasma concentrations can decrease over time even using the long-acting formulation.…”

Section: Introductionsupporting

confidence: 65%

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

Yau¹,

Kinaan²,

Quinn³

et al. 2017

BTT

View full text Add to dashboard Cite

Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional status, differentiation, initial staging, and response to therapy. Octreotide, the first synthetic somatostatin analog, was initially used for the management of gastrointestinal symptoms associated with functional carcinoid tumors. Its commercial development over time led to long-acting repeatable octreotide acetate, a long-acting version that provided greater administration convenience. Recent research demonstrates that octreotide’s efficacy has evolved beyond symptomatic management to targeted therapy with antitumoral effects. This review examines the history and development of octreotide, provides a synopsis on the classification, grading, and staging of neuroendocrine tumors, and reviews the evidence of long-acting repeatable octreotide acetate as monotherapy and in combination with other treatment modalities in the management of non-pituitary neuroendocrine tumors with special attention to recent high-quality Phase III trials.

show abstract

Section: Introductionsupporting

confidence: 65%

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

Yau¹,

Kinaan²,

Quinn³

et al. 2017

BTT

View full text Add to dashboard Cite

show abstract

“…41 Dose escalation may provide longer disease control and was associated with an increased median time to any other intervention from 2.9 to 17.7 months. 42…”

Section: Somatostatin Analoguesmentioning

confidence: 99%

Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review

Pasricha

Padhi

Daboul

et al. 2017

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

“…Whether the observed benefit in progression-free survival coincides with the prolongation of overall survival is unclear. Median survival or overall survival rates were reported in several studies, but the variability in time periods (1-, 2-, and 3-year survival rates were variously reported) made them difficult to compare [24,28,31,34,35,39]. The HR for overall survival in an interim analysis of PROMID was 0.81 (95% CI: 0.30 -2.18; p ϭ .77) [38], with further evaluation of overall survival to be made.…”

Section: Octreotidementioning

confidence: 99%

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

2012

View full text Add to dashboard Cite

Background. For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect antitumor effects in secretory and nonsecretory NETs in addition to symptom control in secretory NETs.Methods. A systematic review of MEDLINE was conducted to identify studies that investigated the antitumor effects of octreotide or lanreotide for patients with NETs. Additional studies not published in the peer-reviewed literature were identified by searching online abstracts.Results. In all, 17 octreotide trials and 11 lanreotide trials that included antitumor effects were identified. Partial response rates were between 0% and 31%, and stable disease

show abstract

Dose Escalation of Octreotide Acetate for Management of Gastro-enteropancreatic Neuroendocrine Tumors

Cited by 17 publications

References 0 publications

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

Contact Info

Product

Resources

About